Elacestrant Impresses in EMERALD Trial of Breast Cancer
By A Mystery Man Writer
Description
![Elacestrant Impresses in EMERALD Trial of Breast Cancer](https://pbs.twimg.com/media/FGGFkeoXEAASeyB.jpg)
Lorenzo Gerratana on X: First results of the EMERALD trial: single agent # elacestrant is a promising new endocrine option, #biomarkers are needed for a real #personalized treatment there is a rapidly progressive endocrine resistant subgroup that needs to
![Elacestrant Impresses in EMERALD Trial of Breast Cancer](https://www.mmm-online.com/wp-content/uploads/sites/2/2022/12/Metabolic.jpg)
Pipeline Report 2022: Patient experience takes center stage
![Elacestrant Impresses in EMERALD Trial of Breast Cancer](https://cdn.sanity.io/images/0vv8moc6/oncnurse/0f83a770b4215778181222a9d279f9e269973f17-646x363.jpg?fit=crop&auto=format)
The HER2+ Breast Cancer Landscape Continues to Change
![Elacestrant Impresses in EMERALD Trial of Breast Cancer](https://mma.prnewswire.com/media/2296569/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg)
Forefront Breaking News
![Elacestrant Impresses in EMERALD Trial of Breast Cancer](https://www.mmm-online.com/wp-content/uploads/sites/2/2022/12/Neurology.jpg)
Pipeline Report 2022: Patient experience takes center stage
![Elacestrant Impresses in EMERALD Trial of Breast Cancer](https://larvolclin.s3.us-west-2.amazonaws.com/resize_16705591576528212656392b5b5dfc89.png)
SABCS 2022: EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
![Elacestrant Impresses in EMERALD Trial of Breast Cancer](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/eca653e380630ffcc2944c6d09e092dd1410afaf-2031x805.png?fit=crop&auto=format)
7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
![Elacestrant Impresses in EMERALD Trial of Breast Cancer](https://image.slidesharecdn.com/breastlandmark-170112195611/85/landmark-trials-in-breast-cancer-80-320.jpg?cb=1710959291)
LANDMARK TRIALS IN BREAST CANCER
from
per adult (price varies by group size)